Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria

article

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1210/JC.2010-2822
P698PubMed publication ID21450987

P50authorJohn BuseQ6224073
Jens Juul HolstQ28373106
Julio RosenstockQ60996888
Michael A. NauckQ64532784
P2093author name stringWolfgang E Schmidt
Alan Garber
Jason H Brett
Nicoline Videbæk
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectantibodyQ79460
liraglutideQ2526479
P304page(s)1695-1702
P577publication date2011-03-30
P1433published inThe Journal of Clinical Endocrinology and MetabolismQ3186902
P1476titleLiraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials
P478volume96

Reverse relations

cites work (P2860)
Q38987110A Plethora of GLP-1 Agonists: Decisions About What to Use and When
Q38020941A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
Q90720927A review of lipidation in the development of advanced protein and peptide therapeutics
Q26801346Adverse Effects of GLP-1 Receptor Agonists
Q38639922An overview of new GLP-1 receptor agonists for type 2 diabetes
Q37517909Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum
Q26992066Biosimilar insulins: guidance for data interpretation by clinicians and users
Q27015789Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
Q40946879Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach
Q37410215Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus
Q37659673Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
Q44669438Comparing diabetes drugs--helping clinical decisions?
Q37992255Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents
Q38005223Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
Q41863397Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus
Q58091552Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys
Q35214425Emerging role of insulin with incretin therapies for management of type 2 diabetes
Q38770746Exenatide: pharmacokinetics, clinical use, and future directions
Q36032335Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc
Q38055195GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
Q38040314GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Q36406821GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.
Q47153467Gastric myoelectric activity during cisplatin-induced acute and delayed emesis reveals a temporal impairment of slow waves in ferrets: effects not reversed by the GLP-1 receptor antagonist, exendin (9-39).
Q88862830Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Q88574215Glucagon-like peptide 1 in health and disease
Q91198085Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Q38542098Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Q36468102Gut hormones: the future of obesity treatment?
Q28081671Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Q38989309Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation.
Q58447924Incretin based therapies: do they hold their promise?
Q26778608Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
Q35760283Incretin therapy--present and future
Q38536672Liraglutide for Type 2 diabetes and obesity: a 2015 update
Q35939660Liraglutide for treating type 1 diabetes
Q36924102Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Q37992254Liraglutide in oral antidiabetic drug combination therapy
Q35580550Liraglutide-induced autoimmune hepatitis
Q38264842Liraglutide: a review of its use in adult patients with type 2 diabetes mellitus
Q37956408Liraglutide: a review of its use in the management of type 2 diabetes mellitus
Q89159597Lixisenatide - A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
Q35372804Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes
Q93174864Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus
Q37929513Next-generation GLP-1 therapy: an introduction to liraglutide
Q35906506Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists
Q38026956Recent advances in incretin-based therapies
Q37340223Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
Q38235219Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials
Q35654002Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.
Q35780935Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
Q30398229Site-specific fatty acid-conjugation to prolong protein half-life in vivo
Q34064982Study of postprandial lipaemia in type 2 diabetes mellitus: exenatide versus liraglutide
Q39140294The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
Q42130324The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide
Q27021870Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Q38006504Update on incretin hormones

Search more.